Premium
THE IN VITRO ACTIVITY OF MOXALACTAM AGAINST 430 CLINICAL, BACTERIAL ISOLATES
Author(s) -
DIGRANES ASBJØRN,
BEISEN EVA,
DIBB WILLIAM L.,
ØSTERVOLD BIRGIT
Publication year - 1982
Publication title -
acta pathologica microbiologica scandinavica series b: microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0108-0180
DOI - 10.1111/j.1699-0463.1982.tb00082.x
Subject(s) - moxalactam , providencia , microbiology and biotechnology , proteus , bacteroides fragilis , haemophilus influenzae , haemophilus , agar dilution , antibiotics , pseudomonas aeruginosa , in vitro , microgram , minimum inhibitory concentration , biology , proteus vulgaris , bacteria , chemistry , cephalosporin , escherichia coli , biochemistry , genetics , gene
The in vitro activity of the novel β‐lactam antibiotic moxalactam against 430 bacterial isolates was determined by an agar dilution method. Moxalactam was highly active against Enterobacteriaceae including indole‐positive Proteus and Providencia , all isolates being susceptible to 1.0 μg/ml or less. The drug was somewhat less active against Gram‐positive cocci and Pseudomonas aeruginosa , and enterococci were highly resistant. All Haemophilus influenzae isolates were inhibited by 0.06 μg/ml or less. Activity against Bacteroides fragilis was good but wide variations of minimal inhibitory concentrations were noted. Moxalactam may become a useful alternative to the aminoglycosides in the treatment of serious infections caused by Gram‐negative bacteria.